International Research Ethics Education and Curriculum Development Award (R25)

PAR-16-081
International Research Ethics Education and Curriculum Development Award (R25)
Department of Health and Human Services
National Institutes of Health

This slideshow requires JavaScript.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-081
Funding Opportunity Title: International Research Ethics Education and Curriculum Development Award (R25)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.172 — Human Genome Research
93.855 — Allergy and Infectious Diseases Research
93.989 — International Research and Research Training
Cost Sharing or Matching Requirement: No
Posted Date: Jan 13, 2016
Creation Date: Jan 13, 2016
Original Closing Date for Applications: May 17, 2018  
Current Closing Date for Applications: May 17, 2018  
Archive Date: Jun 17, 2018
Estimated Total Program Funding:
Award Ceiling: $230,000
Award Floor:

Eligibility

Eligible Applicants:
Native American tribal governments (Federally recognized)
Public and State controlled institutions of higher education
Private institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: See full announcement for complete details.

Additional Information

Agency Name: National Institutes of Health
Description: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The goal of this FIC R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications, by strengthening research ethics capacity in low- and middle-income countries (LMICs) through increasing the number of LMIC research intensive institutions that can provide advanced education in research ethics. Programs supported by this initiative will equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international clinical and public health research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their institutions, governments and international research organizations.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-081.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

eRA Service Desk Monday to Friday 7 am to 8 pm ET http://grants.nih.gov/support/ Phone 1-866-504-9552
Grants Info

FY17 DOD Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP)

Fiscal Year 2017 (FY17) funding opportunities for the Department of Defense (DOD) Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP) that are being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

Applied Research Award

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Deadline: 5:00 p.m. Eastern time (ET), January 25, 2016

• Invitation to Submit an Application: March 7, 2016

• Application Submission Deadline: 11:59 p.m. ET, May 9, 2016

• End of Application Verification Period: 5:00 p.m. ET, May 12, 2016

• Peer Review: July 2016

• Programmatic Review: August 2016

FY17 JPC-2/MIDRP Applied Research Award Focus Areas

To meet the intent of the FY17 JPC-2/MIDRP Applied Research Award (ARA) mechanism, applications MUST specifically address at least one of the FY17 JPC-2/MIDRP ARA Focus Areas related to combat-related or trauma-induced wound infections listed below. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below will not be considered for funding.

FOCUS AREAS:

• Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multipathogen/multi-phenotype characterization of antimicrobial resistance patterns.

• Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical infection management decisions (e.g., optimal wound closure time, optimal duration of antibiotic administration for osteomyelitis).

• Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.

APPLICABLE TO ALL FOCUS AREAS:

• Studies involving carbapenem-resistant organisms are particularly sought.

• Preference will be given to approaches that address infections with one or more MDROs, particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extendedspectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.

• Preference will be given to studies leading toward topical treatments for prevention and management of wound infection.

Clinical Study Award

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Deadline: 5:00 p.m. Eastern time (ET), January 25, 2016

• Invitation to Submit an Application: March 7, 2016

• Application Submission Deadline: 11:59 p.m. ET, May 9, 2016

• End of Application Verification Period: 5:00 p.m. ET, May 12, 2016

• Peer Review: July 2016

• Programmatic Review: August 2016

FY17 JPC-2/MIDRP Clinical Study Award Focus Areas

To meet the intent of the FY17 JPC-2/MIDRP Clinical Study Award (CSA) mechanism, applications MUST contain only one clinical trial/testing with a distinct study design and address at least one of the Focus Areas listed below. Applications focused on areas other than those listed below will not be considered for funding.

FOCUS AREAS:

Therapeutics. Evaluation of optimum preventive or directive therapies for combatrelated or trauma-induced wound infections using Food and Drug Administration (FDA)-approved drugs, biologics, or devices either alone or in combination. Studies focusing on new indications of FDA-approved drugs/biologics/devices or investigational new drugs/biologics/devices will be accepted.

Rapid detection of pathogens and/or anti-microbial drug resistance markers. Evaluation of a functional prototype device or assay for the rapid detection of pathogens and/or anti-microbial drug resistance markers in combat-related or traumainduced wounds. Research outcomes should support the development of an FDA regulated device or assay.

  • Rapid detection of biomarkers. Evaluation of a functional prototype device or assay for the rapid detection of novel and specific in vivo or in vitro biomarkers (from wound, serum, saliva, or urine) that predict development of infection or discriminate between infection and colonization. Research outcomes should support the development of an FDA-regulated device or assay.

APPLICABLE TO ALL FOCUS AREAS:

• Studies involving carbapenem-resistant organisms are particularly sought.

• Preference will be given to approaches that address infections with one or more multidrug-resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.

PRIVATE FOA: American Head and Neck Society Accepting LOIs for Pilot Program Grants

American Head and Neck Society Accepting LOIs for Pilot Program GrantsENT_illustration_small
SOURCE: American Head and Neck Society
APPLICATION DEADLINE: Letters of Intent: 12/15/15.
$ AVAILABLE: Grants of up to $10,000.
ELIGIBILITY: To be eligible, applicants must reside in the United States or Canada and be a medical student, resident, Ph.D., or faculty member at the rank of associate professor or below.
PURPOSE: The American Head and Neck Society is accepting Letters of Intent to its Pilot Grants program.
Grants will be awarded in support of basic, translational, or clinical research projects in head and neck oncology. Clinical or translational research studies are strongly encouraged and should be specifically related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neck neoplastic disease.
CONTACT: Cynthia Zarate, email: Cynthia@ahns.info.

For more information see:

http://www.entnet.org/sites/default/files/uploads/PracticeManagement/Research/_files/2016-ahns-pilot-research-foa.pdf
From The Foundation Center’s Philanthropy News Digest web site, accessed 10/22/15
Subject(s) cancer research

Robert Katzman, MD, Clinical Research Training Fellowship in Alzheimer’s Research

Robert Katzman, MD, Clinical Research Training Fellowship in Alzheimer’s Research

Robert Katzman, MD, Clinical Research Training Fellowship in Alzheimer’s Research Cosponsored by the American Academy of Neurology, the American Brain Foundation, and the Alzheimer’s Association

Application Deadline: October 1, 2015

The American Academy of Neurology, the American Brain Foundation, and the Alzheimer’s Association are pleased to announce a fellowship to support clinical research training in Alzheimer’s. The fellowship is supported by the Alzheimer’s Association, the American Academy of Neurology, and the American Brain Foundation. Each fellowship will consist of a commitment of $55,000 per year for two years, plus $10,000 per year for tuition to support formal education in clinical research methodology at the applicant’s institution or elsewhere. Supplementation of the stipend with other grants or by the fellowship institution is permissible, but fellows may not accept other fellowships, similar awards, or have another source of support for more than 50 percent of their research salary during the first year of a Clinical Research Training Fellowship. If similar awards are obtained after completion of the first year of the Clinical Research Training Fellowship, fellows are required to submit a revised budget for review or may need to forfeit the rest of the award. Only direct costs will be funded by this fellowship.

IMPORTANT DATES October 1, 2015: Application deadline January 2016: Notification of recipients July 1, 2016: Funding begins ELIGIBILITY 1. For the purpose of this fellowship, clinical research is defined as “patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research.” Disease related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases. 2. Applicant must be an AAN member interested in an academic career in clinical research who has completed residency or a post-doctoral fellowship (for a PhD) within the past five years. Those early in their clinical research careers will be given priority. EVALUATION AND SELECTION Applications are evaluated by members of the Clinical Research Subcommittee, Translational Neuroscience Subcommittee, and various ad-hoc reviewers based on the following criteria: • Applicant’s ability and promise as a clinician-scientist based on prior record of achievement and career plan, letters of reference, and curriculum vitae (30 percent) • Quality and nature of the training to be provided and the institutional, departmental, and mentor-specific training environment (30 percent) • Quality and originality of the research plan (40 percent)

For More Information: http://www.alz.org/research/downloads/prog-announce-Katzman.pdf